Despite not achieving its primary endpoint in the pivotal ALSummit trial, Neuronata-R®, an innovative stem cell therapy for amyotrophic lateral sclerosis (ALS), has shown promising clinical improvements in a vital subgroup of patients. Developed by South Korean biotech powerhouse CorestemChemon, the therapy has demonstrated significant efficacy in patients whose disease progression is slower than average. […]
